Skip to main content
The BMJ logoLink to The BMJ
. 1999 Sep 11;319(7211):703–704. doi: 10.1136/bmj.319.7211.703

How to randomise

Douglas G Altman a, J Martin Bland b
PMCID: PMC1116549  PMID: 10480833

We have explained why random allocation of treatments is a required feature of controlled trials.1 Here we consider how to generate a random allocation sequence.

Almost always patients enter a trial in sequence over a prolonged period. In the simplest procedure, simple randomisation, we determine each patient’s treatment at random independently with no constraints. With equal allocation to two treatment groups this is equivalent to tossing a coin, although in practice coins are rarely used. Instead we use computer generated random numbers. Suitable tables can be found in most statistics textbooks. The table shows an example2: the numbers can be considered as either random digits from 0 to 9 or random integers from 0 to 99.

For equal allocation to two treatments we could take odd and even numbers to indicate treatments A and B respectively. We must then choose an arbitrary place to start and also the direction in which to read the table. The first 10 two digit numbers from a starting place in column 2 are 85 80 62 36 96 56 17 17 23 87, which translate into the sequence A B B B B B A A A A for the first 10 patients. We could instead have taken each digit on its own, or numbers 00 to 49 for A and 50 to 99 for B. There are countless possible strategies; it makes no difference which is used.

We can easily generalise the approach. With three groups we could use 01 to 33 for A, 34 to 66 for B, and 67 to 99 for C (00 is ignored). We could allocate treatments A and B in proportions 2 to 1 by using 01 to 66 for A and 67 to 99 for B.

At any point in the sequence the numbers of patients allocated to each treatment will probably differ, as in the above example. But sometimes we want to keep the numbers in each group very close at all times. Block randomisation (also called restricted randomisation) is used for this purpose. For example, if we consider subjects in blocks of four at a time there are only six ways in which two get A and two get B:

1: A A B B 2: A B A B 3: A B B A 4: B B A A 5: B A B A 6: B A A B

We choose blocks at random to create the allocation sequence. Using the single digits of the previous random sequence and omitting numbers outside the range 1 to 6 we get 5 6 2 3 6 6 5 6 1 1. From these we can construct the block allocation sequence B A B A / B A A B / A B A B / A B B A / B A A B, and so on. The numbers in the two groups at any time can never differ by more than half the block length. Block size is normally a multiple of the number of treatments. Large blocks are best avoided as they control balance less well. It is possible to vary the block length, again at random, perhaps using a mixture of blocks of size 2, 4, or 6.

While simple randomisation removes bias from the allocation procedure, it does not guarantee, for example, that the individuals in each group have a similar age distribution. In small studies especially some chance imbalance will probably occur, which might complicate the interpretation of results. We can use stratified randomisation to achieve approximate balance of important characteristics without sacrificing the advantages of randomisation. The method is to produce a separate block randomisation list for each subgroup (stratum). For example, in a study to compare two alternative treatments for breast cancer it might be important to stratify by menopausal status. Separate lists of random numbers should then be constructed for premenopausal and postmenopausal women. It is essential that stratified treatment allocation is based on block randomisation within each stratum rather than simple randomisation; otherwise there will be no control of balance of treatments within strata, so the object of stratification will be defeated.

Stratified randomisation can be extended to two or more stratifying variables. For example, we might want to extend the stratification in the breast cancer trial to tumour size and number of positive nodes. A separate randomisation list is needed for each combination of categories. If we had two tumour size groups (say ⩽4 and >4cm) and three groups for node involvement (0, 1-4, >4) as well as menopausal status, then we have 2×3×2=12 strata, which may exceed the limit of what is practical. Also with multiple strata some of the combinations of categories may be rare, so the intended treatment balance is not achieved.

In a multicentre study the patients within each centre will need to be randomised separately unless there is a central coordinated randomising service. Thus “centre” is a stratifying variable, and there may be other stratifying variables as well.

In small studies it is not practical to stratify on more than one or perhaps two variables, as the number of strata can quickly approach the number of subjects. When it is really important to achieve close similarity between treatment groups for several variables minimisation can be used—we discuss this method in a separate Statistics note.3

We have described the generation of a random sequence in some detail so that the principles are clear. In practice, for many trials the process will be done by computer. Suitable software is available at http://www.sghms.ac.uk/phs/staff/jmb/jmb.htm.

We shall also consider in a subsequent note the practicalities of using a random sequence to allocate treatments to patients.

Table.

Excerpt from a table of random digits.2 The numbers used in the example are shown in bold

89 11 77 99 94
35 83 73 68 20
84 85 95 45 52
56 80 93 52 82
97 62 98 71 39
79 36 13 72 99
34 96 98 54 89
69 56 88 97 43
09 17 78 78 02
83 17 39 84 16
24 23 36 44 14
39 87 30 20 41
75 18 53 77 83
33 93 39 24 81
22 52 01 86 71

References

  • 1.Altman DG, Bland JM. Treatment allocation in controlled trials: why randomise? BMJ. 1999;318:1209. doi: 10.1136/bmj.318.7192.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1990. pp. 540–544. [Google Scholar]
  • 3.Treasure T, MacRae KD. Minimisation: the platinum standard for trials? BMJ. 1998;317:362–363. doi: 10.1136/bmj.317.7155.362. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES